Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Corporation (NASDAQ: XOMA) is a biotechnology royalty aggregator that plays a pivotal role in accelerating the development of groundbreaking therapeutic candidates. With an extensive portfolio of over 70 assets, XOMA acquires potential future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotech companies. This unique model enables XOMA to provide non-dilutive, non-recourse funding to its partners, helping them advance their internal drug candidates or cater to general corporate needs.
Notably, XOMA has pioneered in the discovery and development of antibody therapeutics, leading to over 20 licenses producing milestone and royalty payments in the future. One key asset in their portfolio is X358, an allosteric monoclonal antibody aimed at treating hyperinsulinism by reducing insulin receptor activity.
XOMA has recently expanded its portfolio through strategic acquisitions. In January 2024, the company acquired an economic interest in DSUVIA® (sufentanil sublingual tablet) from Talphera, Inc., for $8 million. DSUVIA® is an FDA-approved pain management option used in supervised medical settings. The agreement stipulates that XOMA will receive all royalties and milestones related to DSUVIA® until $20 million is accrued. Subsequently, royalties will be shared between XOMA and Talphera.
Further broadening its portfolio, XOMA acquired Kinnate Biopharma in April 2024, bringing additional assets into their royalty pipeline. Kinnate’s lead candidates include investigational pan-RAF inhibitor exarafenib and FGFR inhibitor KIN-3248, both targeting cancers with specific genetic alterations.
In April 2024, XOMA announced a $9 million milestone following the FDA approval of Day One Biopharmaceuticals’ OJEMDA™ (tovorafenib), designed to treat pediatric low-grade glioma harboring BRAF alterations. This approval marks a significant addition to XOMA's cash flow and royalty income.
Additionally, XOMA's economic interest in three of Daré Bioscience's women's health products, including the FDA-approved XACIATO™ (clindamycin phosphate) vaginal gel, Ovaprene®, and Sildenafil Cream, 3.6%, signifies their commitment to addressing underrepresented therapeutic areas with significant growth potential.
As of their latest financial results, XOMA reported strong cash reserves and a growing portfolio of commercial and development-phase assets, ensuring long-term sustainability and value creation for shareholders. The company’s disciplined approach to capital deployment and strategic acquisitions highlights its commitment to enhancing human health through biotechnology advancements.
XOMA Corporation has acquired commercial payment and milestone rights for IXINITY® from Aptevo Therapeutics for $9.6 million, aimed at enhancing XOMA's cash flow and royalty aggregation strategy. IXINITY® is used for managing bleeding in Hemophilia B patients. XOMA will start receiving mid-single digit percentage payments from IXINITY® sales, beginning January 1, 2023, until the first quarter of 2035, along with additional milestone payments. This move underscores IXINITY's growth potential within its treatment niche.
XOMA Corporation (Nasdaq: XOMA) has announced cash dividends for its preferred stockholders. Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock will receive $0.53906 per share, while holders of the 8.375% Series B Cumulative Perpetual Preferred Stock will receive $0.52344 per depositary share. The dividends will be paid on April 17, 2023, to shareholders on record by April 4, 2023. XOMA operates as a biotechnology royalty aggregator, managing a diverse portfolio of over 70 assets associated with pre-commercial therapeutic candidates. This strategic focus aids biotech firms in advancing their drug development while providing XOMA with potential financial returns.
XOMA Corporation (NASDAQ: XOMA) reported financial results for 2022, highlighting the acquisition of the Ebopiprant royalty, potentially generating up to $378 million in milestones and royalties from Organon. Revenues dropped to $6.0 million in 2022 compared to $38.2 million in 2021, mainly from milestone payments. The company’s general and administrative expenses increased significantly to $23.2 million, primarily due to salary increases and consulting costs. Notably, the net loss for 2022 reached $17.1 million. However, XOMA expects to generate cash flow from commercial assets, particularly Vabysmo®, with anticipated cash receipts of over $20 million to cover operating expenses in 2023.
XOMA Corporation (NASDAQ: XOMA) announced that Owen Hughes, Executive Chairman, and Brad Sitko, Chief Investment Officer, will participate in a fireside chat at the 43rd Annual Cowen Health Care Conference on March 7, 2023, at 2:10 PM ET.
Investors can access the presentation through a link or via the investor relations section of the company’s website. A replay will be available for 90 days following the event. XOMA is a biotechnology royalty aggregator focused on acquiring future economics from pre-commercial therapeutic candidates, aiding biotech firms in funding internal candidates or general purposes.
XOMA Corporation (Nasdaq: XOMA) announced the granting of stock options to its newly appointed Executive Chairman, Owen Hughes, and Chief Investment Officer, Bradley Sitko, as an inducement for their employment. Hughes received options for 175,000 shares with exercise prices of $18.66 and $30.00, vesting in installments throughout 2023. Sitko was granted options for 550,000 shares, with a similar structure. These inducement awards are outside the company's Long Term Incentive Plan and comply with Nasdaq rules. XOMA focuses on acquiring potential future economics associated with therapeutic candidates.
XOMA Corporation (NASDAQ: XOMA) announced leadership changes on January 4, 2023, with Owen Hughes appointed as Executive Chairman and Brad Sitko as Chief Investment Officer. Former CEO Jim Neal has retired, and the Board believes the new structure will support XOMA's growth as a biotech royalty aggregator. Hughes aims to enhance the company's role in the biotech ecosystem, while Sitko will focus on accelerating the royalty aggregation strategy. XOMA currently holds over 70 royalty assets, positioning it for potential cash flow generation.
XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the Series A stock will receive a dividend of $0.53906 per share, while holders of Series B depositary shares will receive $0.52344 each. These dividends will be paid on January 17, 2023, to shareholders on record as of January 4, 2023. XOMA operates as a biotechnology royalty aggregator, managing a diverse portfolio of over 70 assets related to therapeutic candidates, which it licenses to pharmaceutical companies.
XOMA Corporation has acquired the rights to ebopiprant from ObsEva for $15 million, which includes the Organon License and associated patent estate. The deal allows XOMA to potentially earn up to $475 million in development, regulatory, and sales milestones, plus royalties in the low- to mid-teens upon commercialization. This acquisition marks XOMA's expansion into women's health therapeutics. Ebopiprant has shown promise in reducing preterm labor, with positive results in clinical trials.
XOMA Corporation (Nasdaq: XOMA) announced key financial updates for Q3 2022, reporting total revenues of $0.5 million, down from $0.9 million in Q3 2021. The decline was mainly due to a lack of milestone revenue compared to the previous year. XOMA received its first royalty payment of $0.5 million from Roche related to VABYSMO® sales and also secured $2.5 million from Kuros following Regeneron’s acquisition of Checkmate Pharmaceuticals. The company ended Q3 with $78.3 million cash and no debt, despite a net loss of $4.2 million.
XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A stock will receive $0.53906 per share, while those with the 8.375% Series B stock will receive $0.52344 per depositary share. These dividends are payable on approximately October 17, 2022, to shareholders on record by October 3, 2022. XOMA operates as a biotechnology royalty aggregator, having acquired rights to over 70 assets linked to therapeutic candidates, providing funding to biotechs for their R&D initiatives.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMA)?
What is the market cap of XOMA Royalty Corporation (XOMA)?
What does XOMA Corporation do?
What is XOMA’s business model?
What recent acquisitions has XOMA made?
What are some key assets in XOMA's portfolio?
How does XOMA generate revenue?
What is the significance of XOMA’s investment in X358?
How does XOMA support biotech companies?
What was the financial impact of XOMA’s acquisition of DSUVIA®?
Who are some of XOMA’s partners?
What are XOMA's future plans for growth?
